Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hweb2 re:CPQQ
I tried to enter an order for this stock yesterday, but Ameritrade didn't allow an order because the system didn't recognize the symbol.
After they posted the press release today, I called Ameritrade and they set their system up to recognize orders for this symbol. I picked up a position as well.
RE: SNFCA
The rush of mortgage refinancing definitely benefited their first two quarters. The question is how sustainable are those earnings in this environment?
hweb2 re:HWG
I picked up a position as well.
re:ASRG
I have been buying as well this morning.
hweb2 re:DIRI
The Company has a lot of preferred shares. Do you know if they are convertible?
wade re:CMTP
The preferred share conversion was adjusted from a rate of 1 for 1 pre-split to 10 for 1 post split. Therefore, the preferred shares convert to roughly 750,000 common shares.
I contacted the company to clarify this matter, but I wish the Company would issue a press release regarding the preferred share conversion because there seems to be a lot of confusion among investors.
AGM wow. I sold my shares in the AH in the mid $12s.
iehc 3.5 eps .15
GRVY 2.07 New 52 week high
Bobwins re: GRVY
Glad you got on board. The stock was in need of a catalyst.
UTA-filed a $50m mixed securities shelf offering
Bobwins re: GRVY
That's great news. It is nice to see that the stock is attracting some attention from the professionals.
CMTP CC notes:
I inadvertently posted this on the PSL12 board, so I'm reposting it here.
-The company plans to uplist to either Nasdaq or Amex
-There were several questions regarding guidance. The 2nd half is seasonally the strongest, and it appears managements annual guidance is very conservative.
-The Company is evaluating potential acquisition targets
CMTP CC
-The company plans to uplist to either Nasdaq or Amex
-There were several questions regarding guidance. The 2nd half is seasonally the strongest, and it appears managements annual guidance is very conservative.
-The Company is evaluating potential acquisition targets
2morrowsGains re:CMTP
Absent the company seeking additional financing, the fully diluted share count should remain at these levels. The Company has 7.5m preferred shares that prior to the reverse split they had a mandatory one for one conversion feature.
I contacted the Company to verify whether the preferred conversion was affected by the reverse split, and per their response the conversion of the preferred was adjusted to 10 for 1. Thus, there should be 750k convertible preferred shares.
The current diluted share count appears to include this dilution.
With 10m in cash, it doesn't appear there would be an immediate need to raise additional capital.
re: SRRY
I like srry, but I currently don't hold a position. Based on managements comments in the first quarter earnings release, it appears the second quarter might not be as strong as the first quarter, but the future looks more positive.
While we expect our margins and profitability to return to customary levels in the second quarter, we believe that our joint venture with Close The Loop as well as other initiatives to be announced shortly positions us for growth during the latter part of the year and into 2010.”
COT breaks back above $6
Another example of how a stock gets pressed lower to get a favorable price for the secondary purchasers followed by a bounce after it's priced.
You've got to love wall street.
COT picked up some shares last night at 5.36
COT posted a blowout quarter of .48/s(including .12 tax benefit) and proceeded to sell-off dramatically. The sell-off appeared to be related to the Company's announcement of a secondary offering.
Last night the Company announced that the offering was priced at 5.3 with a total of 9.4m shares. With the offering out of the way, I'm hoping the stock will trend up from here.
Their second quarter ended June 30, 2009.
Note re: GRVY 2nd quarter earnings
Due to the fact that GRVY is a foreign filer, they aren't required to report quarterly data similar to US filers. As a result the Company has historically reported quarterly data on an inconsistent schedule.
I contacted the Company regarding the timing of the second quarter earnings release. Per Yoon Joo, the company plans to release the 2nd quarter earnings at the end of August. This is much earlier then last years second quarter which was during the middle of October.
Per Yoon Joo, she is planning to include the EPS information in the second quarter earnings release.
I've posted some dd on GRVY on another board that I've reproduced below,
Post #1
-The stock currently trades at 1.53.
-They have Cash and short term investments of 1.89/s
-Stockholders Equity of 2.31/s
-1st quarter eps of .15 versus a prior year loss of -.13
GRVY is a Korean online game developer. This is a NasdaqNM stock. They are audited by PriceWaterHouse.
They have two games under development which should launch in the near future. Ragnarok Online II is the second version of their primary revenue generator and Ice Age. Ragnarok Online II is expected to launch in the first half of 2010, and Ice age is expected to launch in the fall 2009.
The company's press release didn't include an EPS calculation, and they released it on the GlobeNewswire.
The company has 27.8 million equivalent ADR shares with just over 7 million float.
I like the risk reward profile.
Post #2
Another followup note regarding Gravity. The company holds a 16% in interest in Online Game Revolution Fund. The fund invests in the development of online games.
It appears they are supposed to launch a long awaited game called Grandia Online in August of 2009.
The significance to Gravity is that they use the equity method of accounting for their 16% ownership interest. This has resulted in a fairly significant expense on the income statement.
When a game is under development all of the costs get expensed until it is proven feasible after that point the costs get capitalized. With the launch of Grandia, it is possible they may be able to start recognizing a return from their investment in the fund.
I'm happy to see the acceleration in volume.
It will be interesting to see if the momentum traders can be drawn into this stock.
10 Bagger re: GRVY
Based on my notes Gung Ho owns 59%, Moon Capital 8.5% and Ramius 6.4%.
Gung Ho was the developer of Grandia Online which they sold to Online Game Revolution Fund.
Gravity holds a 16% interest in the Online Game Revolution Fund, and I'm guessing that Gung Ho probably holds an interest in that fund as well.
Based on the inter-relationships, I'm assuming that Gung Ho's ownership interest is going to remain stable.
Gravity already has 1.89/ share cash and equivalents. Due to accounting rules related to the amortization and expensing of software development costs, the Company has traditionally been able to generate stronger cash from operations then net income. Thus, if they are able to produce positive net income, it should result in a very favorable impact on their cash balance.
10 bagger re: GRVY
I'm well aware of GRVY's share count and first quarter eanings release. I've posted that information previously on this board.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39982905
My point to the Company is that they would attract more attention from new investors if they didn't require the investors to research that calculation independently.
re: GRVY
I contacted the Company to encourage that they reissue the first quarter earnings release with an earnings per share (eps) calculation.
They are not going to reissue the first quarter release due to the fact that the second quarter results will be released soon. They are, however, going to seriously consider including the earnings per share calculation in future earnings releases.
They did agree with my assessment that new investors were likely to miss the significance of the excellent results due to the lack of an eps calculation.
MEDQ: .02 eps for the 2nd quarter
I haven't had time to look into the numbers.
re: GRVY
Another followup note regarding Gravity. The company holds a 16% in interest in Online Game Revolution Fund. The fund invests in the development of online games.
It appears they are supposed to launch a long awaited game called Grandia Online in August of 2009.
The significance to Gravity is that they use the equity method of accounting for their 16% ownership interest. This has resulted in a fairly significant expense on the income statement.
When a game is under development all of the costs get expensed until it is proven feasible after that point the costs get capitalized. With the launch of Grandia, it is possible they may be able to start recognizing a return from their investment in the fund.
JNGW a CHVMC09 underperformer
Current price .9 down 5% in 2009
Market capitalization of 15.34m with 17.05m shares outstanding
Cash balance .38/s.
1st quarter eps.04 (hopefully that was trough eps for the company)
2008 eps .53
2007 eps .49
Trade receivables are high, but the Company had .07/s in positive cash flow from operations in the 1st quarter.
I'm hoping that the recovery in China's economy will result in a sequential increase in JNGW's revenues and eps. I have been accumulating shares a head of earnings.
Hidden Gem ? GRVY
-The stock currently trades at 1.53.
-They have Cash and short term investments of 1.89/s
-Stockholders Equity of 2.31/s
-1st quarter eps of .15 versus a prior year loss of -.13
GRVY is a Korean online game developer. This is a NasdaqNM stock. They are audited by PriceWaterHouse.
They have two games under development which should launch in the near future. Ragnarok Online II is the second version of their primary revenue generator and Ice Age. Ragnarok Online II is expected to launch in the first half of 2010, and Ice age is expected to launch in the fall 2009.
The company's press release didn't include an EPS calculation, and they released it on the GlobeNewswire.
The company has 27.8 million equivalent ADR shares with just over 7 million float.
I like the risk reward profile.
http://finance.yahoo.com/news/Gravity-Reports-First-Quarter-pz-3724964715.html?x=0&.v=1
Seoul, South Korea — July 8, 2009 — GRAVITY Co., Ltd. (NasdaqGM: GRVY), an online game developer and publisher based in South Korea, today announced its unaudited financial results for the first quarter ended March 31, 2009, prepared in accordance with generally accepted accounting principles in the United States.
Revenues for the first quarter ended March 31, 2009 was KRW 16,607 million (US$ 12,991), representing a 9.27% increase from KRW 15,198million (US$ 11,889 thousand) for the fourth quarter ended December 31, 2008 (“QoQ”) and a 32.55% increase from KRW 12,529 million (US$ 9,801 thousand) for the first quarter ended March 31, 2008 (“YoY”).
REVIEW OF FINANCIAL RESULTS
Revenues
Royalty and licensing fee revenues for the first quarter ended March 31, 2009 were KRW 10,816 million (US$ 8,461 thousand), representing a 16.99% increase QoQ from KRW 9,245 million (US$ 7,232 thousand) and a 56.82% increase YoY from KRW 6,897 million (US$ 5,395 thousand). The increase was primarily driven by higher Japan revenues from Ragnarok Online resulting from the weakening of the Korean Won against the Japanese Yen and contributed to increased revenues in Japan.
Subscription revenues for the first quarter of 2009 was KRW 3,475 million (US$ 2,718 thousand), representing a 12.28% increase QoQ and a 21.50% increase YoY compared to KRW 3,095 million (US$ 2,421 thousand) and KRW 2,860 million (US$ 2,237 thousand), respectively. The increased subscription revenues QoQ mostly came from increased revenues from Ragnarok Online in the U.S., Canada and Korea. The increase in revenues YoY were attributed to increased revenues from micro-transactions of Ragnarok Online in the U.S. and Canada and commercialization of Requiem in the U.S., Canada, Russia and CIS countries in June 2008. This increase was offset by decreased revenues from Ragnarok Online and Requiem in Korea.
Mobile game revenues was KRW 1,852 million (US$ 1,449 thousand) for the first quarter of 2009, representing a 4.57% increase QoQ from KRW 1,771 million (US$ 1,385 thousand) and a 30.33% increase YoY from KRW 1,421 million (US$ 1,112 thousand).
Character merchandising, animation and other revenue was KRW 464 million (US$ 363 thousand) for the first quarter of 2009, representing a 57.31% decrease QoQ from KRW 1,087 million (US$ 851 thousand) and a 65.66% decrease YoY from KRW 1,351 million (US$ 1,057 thousand). The decrease QoQ was mainly due to the decreased revenues from Ragnarok DS in Japan in the first quarter of 2009 compared with its higher revenues when it was released in December 2008 and partly resulted from the decreased sales of mobile phone accessories by NeoCyon, a subsidiary of the Company. The decrease YoY was primary due to decrease in sales of mobile phone accessories by NeoCyon.
Cost of Revenues and Operating Expenses
Cost of revenues were KRW 5,427 million (US$ 4,245 thousand) for the first quarter of 2009, representing a 10.10% decrease QoQ from KRW 6,037 million (US$ 4,722 thousand) and a 27.68% decrease YoY from KRW 7,504 million (US$ 5,870 thousand). The Company’s decreased cost of revenues QoQ was attributed to completion of the amortization on intangible assets in December 2008, which occurred when the Company acquired NeoCyon in November and December 2005. The decrease in cost of revenues YoY was mainly due to decreased cost of revenues related to mobile phone accessories, reduced amortization on intangible assets.
Operating expenses were KRW 5,667 million (US$ 4,433 thousand) for the first quarter of 2009, representing a 21.57% decrease QoQ from KRW 7,226 million (US$ 5,653 thousand) and a 15.56% decrease YoY from KRW 6,711 million (US$ 5,250 thousand). The decrease in operating expenses QoQ was mostly due to the decrease in commission paid and advertising expenses. The YoY decrease in operating expenses was attributed to i) decreased rent expenses which were due to relocation of the headquarter office in Seoul on February 1, 2008; the rent expenses for both old and new offices occurred between February 1, 2008 and Mar 16, 2008 as the lease agreement of the old office expired on March 16, 2008, which did not recur in the first quarter of 2009; ii) decreased R&D expenses; and iii) decrease in advertising expenses.
Income before income tax expenses and others was KRW 6,997 million (US$ 5,474 thousand) for the first quarter of 2009, which represents a 76.03% increase QoQ compared with KRW 3,975 million (US$ 3,110 thousand) and a 2,616.91% increase YoY compared with KRW 278 million losses (US$ 217 thousand).
As a result of the foregoing factors, Gravity recorded a net income of KRW 5,253 million (US$ 4,109 thousand) for the first quarter of 2009 compared with a net income of KRW 1,654 million (US$ 1,294 thousand) for the fourth quarter of 2008 and a net loss of KRW 4,513 million (US$ 3,531 thousand) for the first quarter of 2008.
The balance of cash and cash equivalents and short-term financial instruments was KRW 67,233 million (US$ 52,596 thousand) as of March 31, 2009.
Note: For convenience purposes only, the KRW amounts have been expressed in U.S. dollars at the rate of KRW 1,278.3 to US$ 1.00, the noon buying rate in effect on June 26, 2009 as quoted by the Federal Reserve Bank of New York.
hweb2
I listened to the CC last night. I agree with your assessment that the results may not be sustainable. They recorded $5m in revenues related to Saudi Arabia that will not recur in the 3rd quarter.
One caller inquired about whether the company would be profitable in the 3rd and 4th quarters. I don't recall the exact response from management, but my recollection was that they wouldn't guarantee it.
I think the company has potential, but it is very difficult to forecast what forward earnings will be.
I wonder if Germany is considering using their products based on the caller that asked several questions related to their capacity in Germany.
COT 7.245 posted a big quarter
COT is primarily a carbonated beverage company. They reported .48 for the quarter. That included a tax benefit of roughly .12 per share.
The company expects lower margins in the second half, and they may issue stock to retire debt, so it is difficult to forecast what eps will be in the second half.
Based on the CC it appears magins may be 2% lower than the first half which would reduce quarterly eps by .12 based on the 2nd quarter revenues. There does, however, appear to be seasonality in revenues.
If revenues and other expenses remain stable with the second quarter it looks like they may be able to report .2 to .25 eps going forward.
http://finance.yahoo.com/news/Cott-Reports-Second-Quarter-iw-1884561063.html?x=0&.v=1
TRIB
Picked up a few shares. The stock has sold off after posting .14 in eps for the 2nd quarter.
http://finance.yahoo.com/news/Trinity-Biotech-Announces-iw-3218391006.html?x=0&.v=1
sskillz1 re: SPAN
SPAN does release tonight with the CC at 10 am Eastern time tomorrow.
This is my second largest holding. I'm not sure what the quarterly number will be, but the fact that management has guided for the second half earnings to exceed the first half earnings of .71 makes this stock a value at this price.
IDSA 7.39 pre-announced 2nd qtr eps of .24-.26 and continues it's trend higher. Another stock I sold too early.
hweb2 re: CKSW
I can add this to the growing list of stocks that I underestimated the upside potential.
If I remember correctly last q they reported the book to bill and not the backlog. This quarter they reported the backlog but not the book to bill, so it is a little difficult to determine the trend in the business.
Deferred revenues did decline sequentially from 8.3m to 6.4m, and I'm guessing that the book to bill may have been below 1.
Based on their guidance of exceeding the revenues for the 2nd half of 2008, they should be able to report at least 15m in revenues for the next two quarters. That should result in at least .40 in eps for 2009.
The stock definitely looks fairly valued above $7.
swick984 re: MEDQ
I saw that filing as well. I'm curious if the party that received the distribution will decide to liquidate the position. If so, it could pressure the stock in the near term.
mandjb yes
TRIB received FDA approval of their Destiny Max
DUBLIN, IRELAND -- (Marketwire) -- 07/07/09 -- Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the FDA approval and US launch of its high throughput haemostasis analyzer, the Destiny Max.
Trinity has today obtained FDA approval of its Destiny Max analyzer and is now launching the instrument in the U.S. market with immediate effect. The target market for the instrument includes university hospitals, high throughput general hospitals, high volume commercial laboratories and reference laboratories.
Key features of the Destiny Max include:
-- being the only high throughput instrument on the worldwide market that
allows simultaneous and automated measurement of mechanical and optical
clot detection, chromogenic and immuno-turbidimetric assays;
-- best in class graphical user interface and touch screen technology;
-- the most reliable and novel cap piercing solution on the market.
As part of its U.S. launch Trinity will be showcasing the Destiny Max at the ISTH Congress in Boston on 11-16 July, 2009 and at the AACC Clinical Lab Expo in Chicago on 21-23 July, 2009.
Commenting on the approval Ronan O'Caoimh, CEO said, "I am delighted to announce FDA approval of the Destiny Max analyzer for the U.S. market. This follows the successful launch of Destiny Max in Europe and other international markets, following CE mark approval in December, 2008. The FDA approval and U.S. launch of Destiny Max represents a key strategic milestone for Trinity. This completes the roll out of Destiny Max in all major worldwide markets thus providing Trinity with access to the high throughput haemostasis market, estimated to be US$500 million per annum.
This approval by the FDA significantly improves the marketability of the analyzer and represents a clear endorsement of Trinity's ability to integrate hardware, software, reagents and consumables into a new state-of-the-art instrument platform that will exceed customer expectations. In the few short months since its international launch we have already enjoyed considerable success with the Destiny Max globally with sales in Japan, China, Italy, Ireland, the Netherlands, Germany, Australia, Turkey and the United Kingdom. Based on the market reaction we have received to date, I am more convinced than ever that we now have the best haemostasis instrument available on the market today.
The combination of Destiny Max with our mid-throughput Destiny Plus and other instruments, in conjunction with our comprehensive reagent portfolio and strong service commitment means that Trinity is now in a leading position to offer a complete and best in class heamostasis product range to all customers in the market. This will undoubtedly act as a key driver for the growth of our haemostasis business going forward, which we expect will result in a significant increase in our market share."
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
MEDQ 5.82 +.63
Yesterday they announced the settlement of a patent infringement lawsuit.
The new management has continued to settle the past legal issues which should provide them the opportunity to focus on managing operations.
The stock appears to have broken through the resistance in the $5-$5.5 range.
mandjb good job on IFON.
You did much better than me. I purchased a large number of shares in the mid .40s and sold in the .7 to .8 range. This is just another in a long list of stocks that I've sold way too early.